Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Looking at 'Strategic Options' for 454 as Unit's Revenues Soar in Q2

NEW YORK (GenomeWeb News) – CuraGen hired investment bank Goldman Sachs “to examine strategic options" for its investment in 454 Life Sciences, the company said today.
 
It did not provide additional information about this new strategy.
 
CuraGen made the disclosure as it reported that revenue from 454 helped overall receipts more than double.
  
CuraGen's total revenues for the three months ended June 30 surged to $10.7 million from $4.3 million during the same period a year ago. 454 contributed $9.8 million in revenues for the quarter, almost three times more than the same period last year.
454's receipts included $5.4 million from sales of its GS20 DNA sequencer and reagents and $2.3 million in service revenue from its sequencing center.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.